Список литературы

Поставить закладку

Isidori A. et al. Iron toxicity - Its effect on the bone marrow. // Blood Rev. England, 2018. Vol. 32, № 6. P. 473–479.
Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options? // Blood. 2013. Vol. 122, № 22. P. 3561–3567.
Frickhofen N. et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia // Blood. 2003. Vol. 101, № 4. P. 1236–1242.
Kulasekararaj A.G. et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome // Blood. 2014. Vol. 124, № 17. P. 2698–2704.
Afable M.G., Tiu R. V, Maciejewski J.P. Clonal Evolution in Aplastic Anemia // Hematology. 2011. № 1. P. 90–95.
Pu J.J. et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia // Eur. J. Haematol. 2011. Vol. 87, № 1. P. 37–45.
Socié G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors // Lancet. 1996. Vol. 348, № 9027. P. 573–577.
Kulagin A. et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study // Br. J. Haematol. 2014. Vol. 164, № 4. P. 546–554.
Li Y. et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience // Ann. Hematol. 2011. Vol. 90, № 5. P. 529–537.
Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
Kaufman D.W. et al. Relative incidence of agranulocytosis and aplastic anemia // Am. J. Hematol. 2006.
Killick S.B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. // Br. J. Haematol. England, 2016. Vol. 172, № 2. P. 187–207.
Dokal I. Dyskeratosis congenita. // Hematology. 2011. Vol. 2011. P. 480–486.
Soulier J. Fanconi anemia. // Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 492–497.
Marsh J.C.W. et al. Guidelines for the diagnosis and management of aplastic anaemia // Br. J. Haematol. 2009. Vol. 147, № 1. P. 43–70.
Михайлова Е.А., Савченко В.Г. Протокол программного лечения больных апластической анемией: комбинированная иммуносупрессивная терапия // Программное лечение заболеваний системы крови / ed. В.Г.Савченко. Москва: Практика, 2012. P. 135–150.
Peslak S.A., Olson T., Babushok D. V. Diagnosis and Treatment of Aplastic Anemia // Current Treatment Options in Oncology. Springer New York LLC, 2017. Vol. 18, № 12.
Nielsen P. et al. Iron Stores in Patients with Myelodysplasia and Aplastic Anemia. // Blood. 2006. Vol. 108, № 11. P. 3726–3726.
Детская гематология. Клинические рекомендации / ed. Румянцев А.Г., Масчан А.А., Жуковская Е.В. М.: ГЭОТАР-Медиа, 2015. 656 p.
Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. // Hematology. 2007. P. 29–39.
de Latour R.P., Risitano A.M., Dufour C. Severe Aplastic Anemia and PNH // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 579–587.
Barone A. et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP) // Blood Cells, Mol. Dis. Elsevier B.V., 2015. Vol. 55, № 1. P. 40–47.
Frisch B., Lewis S.M. The bone marrow in aplastic anaemia: diagnostic and prognostic features // J. Clin. Pathol. 1974. Vol. 27, № 3. P. 231–241.
Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies // Blood. 2008. Vol. 112, № 4. P. 965–974.
Maciejewski J.P. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia // Blood. 2002. Vol. 99, № 9. P. 3129–3135.
Gupta V. et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults // Br. J. Haematol. 2006. Vol. 134, № 1. P. 95–99.
Babushok D.V., Bessler M., Olson T.S. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults // Leuk Lymphoma. 2016. Vol. 57, № 3. P. 520–536.
Shimano K.A. et al. Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium // Hematology. 2021. Vol. 96, № 11. P. 1491–1504.
Zar H.J., Andronikou S., Nicol M.P. Advances in the diagnosis of pneumonia in children // BMJ. British Medical Journal Publishing Group, 2017. Vol. 358.
Михайлова Е.А. et al. Комбинированная иммуносупрессивная терапия больных апластической анемией: повторные курсы антитимоцитарного глобулина // ГЕМАТОЛОГИЯ И ТРАНСФУЗИОЛОГИЯ. 2014. Vol. 59, № 4. P. 11–18.
Young N.S., Bacigalupo A., Marsh J.C.W. Aplastic Anemia: Pathophysiology and Treatment // Biol. Blood Marrow Transplant. 2010. Vol. 16, № 1. P. S119–S125.
Bacigalupo A. How I treat acquired aplastic anemia // Blood. 2017. Vol. 129, № 11. P. 1428–1436.
Scheinberg P., Young N.S. How I treat acquired aplastic anemia. // Blood. 2012. Vol. 120, № 6. P. 1185–1196.
Desmond R. et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug // Blood. 2014. Vol. 123, № 12. P. 1818–1825.
Kelsey P. et al. Guidelines for the use of platelet transfusions // Br. J. Haematol. 2003. Vol. 122, № 1. P. 10–23.
Hartung H.D., Olson T.S., Bessler M. Acquired Aplastic Anemia in Children // Pediatr. Clin. North Am. NIH Public Access, 2013. Vol. 60, № 6. P. 1311.
Bacigalupo A. et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups // Haematologica. Haematologica, 2012. Vol. 97, № 8. P. 1142–1148.
Scheinberg P. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia // N. Engl. J. Med. 2011. Vol. 365, № 5. P. 430–438.
Chen M. et al. Posaconazole as primary prevention of fungal infection in intensive immunosuppressive therapy for severe aplastic anemia // Zhonghua Xue Ye Xue Za Zhi. 2018. Vol. 39, № 2. P. 128–131.
Valdez J.M. et al. Infections in patients with aplastic anemia // Semin. Hematol. Semin Hematol. 2009. Vol. 46, № 3. P. 269–276.
Townsley D.M. et al. Eltrombopag added to standard immunosuppression for aplastic anemia // N. Engl. J. Med. 2017. Vol. 376, № 16. P. 1540–1550.
Goronkova O. et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia // Blood Adv. 2023. Vol. 7, № 6. P. 953–962.
Guo H. et al. Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials // Hematology. 2024. Vol. 29, № 1; 2335419.
Lee J.W. et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial // Blood. 2010. Vol. 116, № 14. P. 2448–2454.
Hong Y. et al. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis. // Clin. Drug Investig. 2019. Vol. 39, № 2. P. 141–156.
Горонкова О.В. и соавт. Применение элтромбопага у детей и молодых взрослых с приобретенной апластической анемией // Вопросы гематологии/онкологиии и иммунопатологии в педиатрии. 2017. Vol. 16, № 2. P.17–25.
Богачева Н.Ю., Шнейдер М.М., Масчан А.А. “Циклоспориновая зависимость” при лечении тяжелой апластической анемии у детей // Гематология и трансфузилогия. 1996. Vol. 41, № 2. P. 18–21.
Sanders J.E. et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia // Blood. 2011. Vol. 118, №5. Р. 1421-1428.
L’Hotta A.J. et al. Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review // CA Cancer J Clin. 2023. Vol. 73, № 5. Р. 524-545.
Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87–99.
Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77–87.
Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1–2. P. 423–432.
Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123–127.
Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
Hübel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117–123.
Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131–137.
Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127–131.
Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137–143.
Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike // Bone Marrow Transplant. 2012 471. Nature Publishing Group, 2011. Vol. 47, № 1. P. 5–14.
Ruutu T. How to use busulfan in conditioning for allogeneic transplantation // Cell. Ther. Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, № 1. P. 18–20.
Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation // Clin. Pharmacokinet. Springer, 2019. Vol. 58, № 5. P. 627.
Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide // Bone Marrow Transplant. 2020 557. Nature Publishing Group, 2020. Vol. 55, № 7. P. 1272–1281.
Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 2. P. e157–e167.
Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplant. 2010 457. Nature Publishing Group, 2009. Vol. 45, № 7. P. 1161–1166.
Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biol. Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, № 1. P. 112.
Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, № 2. P. 224.
Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 3. P. 522–530.
Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis // Ann. Hematol. 2021. Vol. 100, № 3. P. 779–787.
Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Elsevier, 2011. Vol. 17, № 12. P. 1862–1868.
Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biol. Blood Marrow Transplant. 2013. Vol. 19. P. 12–21.
Schäfer H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Ann. Hematol. 2021 1008. Springer, 2021. Vol. 100, № 8. P. 2095–2103.
Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood. Content Repository Only!, 2017. Vol. 130, № 20. P. 2186–2195.
Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2–2. P. 1012–1025.
Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 136, № 4. P. 429–440.
Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 135, № 19. P. 1630–1638.
Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // J. Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1–10.
Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // Int. J. Hematol. 2019 1094. Springer, 2019. Vol. 109, № 4. P. 491–498.
Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatr. Transplant. Pediatr Transplant, 2014. Vol. 18, № 1. P. 94–102.
Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // Am. J. Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, № 3. P. 319–326.
Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biol. Blood Marrow Transplant. Elsevier, 2019. Vol. 25, № 4. P. 743–748.
Sleight B.S. et al. Infliximab for GVHD therapy in children // Bone Marrow Transplant. 2007 405. Nature Publishing Group, 2007. Vol. 40, № 5. P. 473–480.
Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatr. Transplant. Pediatr Transplant, 2007. Vol. 11, № 3. P. 306–309.
Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatr. Int. Pediatr Int, 2010. Vol. 52, № 3. P. e161-3.
Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2015. Vol. 21, № 6. P. 1083–1090.
Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331–347.
Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, № 12. P. 945–956.
Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 3. P. 389-401.e1.
Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189–197.
Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259–265.
Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281–291.
Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273–281.
Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 8.
Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387–393.
Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315–323.
Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 1. P. e61–e72.
Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, № 1. P. 7–16.
Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, № 10. P. 2365–2372.
Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatr. Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, № SUPPL. 7. P. 25–36.
Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, № 2. P. 181–190.
Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171–177.
Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163–171.
Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, № 5. P. 662–667.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.
Ye M. et al. Effectiveness of exercise rehabilitation on aplastic anemia patients receiving hematopoietic stem cell transplantation: study protocol for a randomized controlled trial //Trials. – 2024. – Т. 25. – №. 1. – С. 361.
Bercovitz RS., Josephson CD. Transfusion considerations in pediatric hematology and oncology patients. Hematol Oncol Clin North Am. 2016; 30(3): 695-709. doi: 10.106/j.hoc.2016.01.010.
Steiner ME, Zantek ND, Stanworth SJ, Parker RI, et al. Recommendations on RBC Transfusion Support in Children With Hematologic and Oncologic Diagnoses From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatr Crit Care Med. 2018 Sep;19(9S Suppl 1): 149-156.
Shah N., Andrews J., Goodnough LT. Transfusions for anemia in adult and pediatric patients with malignancies. Blood Reviews. 2015; 29(5): 291-299. doi: 10.106/j.blre.2015.02.001
Yoshimi A. et al. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children //Blood, The Journal of the American Society of Hematology. – 2013. – Т. 121. – №. 5. – С. 860-861.
Трахтман П.Е., Старостин Н.Н., Новичкова Г.А., Ворожцов И.Н. Трансфузионная терапия в клинической практике: учеб. пособие / Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Д. Рогачева. Москва, 2021. 76 с.
Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. Москва: МЕДПРАКТИКА-М, 2009. 448 с.
Румянцев А. Г. Федеральные клинические рекомендации по организации оптимально венозного доступа у детей с гематологическими, онкологическими и иммунологическими заболеваниями. / А. Г. Румянцев, А. А. Масчан, Д. Ш. Биккулова. – 2015.
Венозный катетер. Использование, уход, контроль, осложнения: учебное пособие / Сацук А.В., Солопова Г.Г., Щукин В.В., Литвинов Д.В., Пименова О.В. Климова Н.А., Щемелинская Ю.Л., Масчан А.А, Новичкова Г.А. – М. АО «Информатика», 2023. - 152 с.: ил. ISBN 978-5-6049537-2-3.115. Erin Gatza et al. Prevention and treatment of acute grft-versus-host disease in children, adolescents and young adults. Biol Blood marrow Transplant 2020; May; 26(50: e101-e112.
Simon A. et al. Surveillance of bloodstream infections in pediatric cancer centers – what have we learned and how do we move on? // GMS Hyg Infect Control. German Medical Science, 2016. Vol. 11. P. Doc11.
Bard J.D., TeKippe E.M.E. Diagnosis of Bloodstream Infections in Children // J Clin Microbiol. J Clin Microbiol, 2016. Vol. 54, № 6. P. 1418–1424.
Petty L.A. et al. Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome? // Pediatr Blood Cancer. Pediatr Blood Cancer, 2016. Vol. 63, № 7. P. 1244–1249.
Scheler M. et al. Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland // Infection. Springer Science and Business Media Deutschland GmbH, 2020. Vol. 48, № 4. P. 607–618.
Vehreschild M.J.G.T. et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies // J Antimicrob Chemother. J Antimicrob Chemother, 2014. Vol. 69, № 12. P. 3387–3392.
Jaiswal S.R. et al. Gut Colonization with Carbapenem-resistant Enterobacteriaceae Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of A Prospective Surveillance Study // Mediterr J Hematol Infect Dis. Catholic University in Rome, 2018. Vol. 10, № 1. P. 2018025.
Girmenia C. et al. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey // Clin Infect Dis. Clin Infect Dis, 2017. Vol. 65, № 11. P. 1884–1896.
Klastersky J., Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. CID, 2004; 39(1): 32-37
Morrissey C., Gilroy N., Macesic N., Walker P., Nanda-Rajah M. et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J, 2014; 44: 1298–1314.
Soderman M. et al Frequent respiratory viril infections in children with febrile neutropenia – a prospective follow-up study/ PLoS One 2016;11(6):1-13. Cahuapaza-Gutierrez N.L. “Aplastic anemia in the light of the COVID-19 pandemic:infection,vaccination,and pathophysiologic mechanisms”. Ann Hematol 2024 doi.org/10.1007/s00277-024-06052-9
Barr R.S., Drysdale S.B. Viral respiratory tract infections in the immunocompromised child. Pediatr Infect Dis J 2023;42(5):170-172. Pawelec K. et al “Respiratory and systemic infections in children with severe aplastic anemia on immunosuppressive therapy” Adv Exp Med Biol 2013:788:417-25
Солопова Г.Г., Цыганова Е.В., Кондрашова А.В., Гордеева Г.Н., Розанцева Е.В., Бегунова С.В., Воронин К.А., Копосова А.О., Новичкова Г.А. «Особенности течения новой коронавирусной инфекции COVID-19 у детей с онкологическими, онкогематологическими и тяжелыми иммунологическими заболеваниями. Опыт НМИЦ ДГОИ им. Дмитрия Рогачева». Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021 т.20 №4: 89-99
Spruit J L, Knight T, Sweeney C, Salimnia H, Savaşan S. Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations Pediatr Hematol Oncol. 2020 Apr;37(3):211-222. doi: 10.1080/08880018.2019.1711473
Tai E, Richardson LC, Townsend J, Howard E, Mcdonald LC Clostridium difficile infection among children with cancer Pediatr Infect Dis J. 2011 Jul;30(7):610-2.
Castagnola E., Ruberto E., Guarino A. Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000 // World J Gastroenterol. Baishideng Publishing Group Inc, 2016. Vol. 22, № 25. P. 5853.
Maertens J.A. et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay // Clin Infect Dis. Clin Infect Dis, 2007. Vol. 44, № 10. P. 1329–1336.
Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L. Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016 Nov 15;63(10):1340-1348. doi: 10.1093/cid/ciw592
Warris A , Lehrnbecher T Progress in the Diagnosis of Invasive Fungal Disease in Children Curr Fungal Infect Rep. 2017;11(2):35-44. doi: 10.1007/s12281-017-0274-9.
Gupta A, Capoor MR, Shende T, Sharma B, Mohindra R, Suri JC, Gupta DK. Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies. J Lab Physicians. 2017 Oct-Dec;9(4):234-238. doi: 10.4103/JLP.JLP_127_16.
Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222. doi: 10.1186/cc9365
Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016 Jun;59(6):374-8. doi: 10.1111/myc.12482
Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. . Lancet Infect Dis. 2024 Feb 9:S1473-3099(23)00731-4. doi: 10.1016/S1473-3099(23)00731-4.
Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017 Jun 20;35(18):2082-2094. doi: 10.1200/JCO.2016.71.7017
Lehrnbecher T. et al. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update // J Clin Oncol. J Clin Oncol, 2023. Vol. 41, № 9. P. 1774–1785.
Lehrnbecher T. et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation // Lancet Oncol. Lancet Oncol, 2021. Vol. 22, № 6. P. e270–e280.
Солопова Г.Г., Новичкова Г.А. Опыт внедрения алгоритма эмпирической антибактериальной терапии при развитии фебрильной нейтропении в Центре детской гематологии/онкологии // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017. Vol. 16, № 3. P. 35–47.
Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference of Infections in Luekemia. Нaematologica 2013; 98 (12): 1826-1835
Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol, 2009; 31(9): 623-629
Tam CS, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K et al. Use of empiric antimicrobial therapy in neutripenic fever. Intern Med J, 2011; 41: 90-101
Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B et al. Guidlenes for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Сlin Оncol, 2012; 30(35): 4427-4438
Ruhnke M and Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol, 2016; 7(6): 345–359
Tissot F., Agrawai S., Pagano L., Petrikkos G., Groll A.H. et al. ECIL-6 Guidelines for the Treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Liekemia and Hematopoietic Stem Cell Transplant Patients. Hematologica, 2017; 102: 433-444
Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H et al. Empirical versus antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis, 2009; 48:1042–1051
Groll AH, Pana D, Lanternier F, Mesini A, Ammann RA8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021 Jun;22(6):e254-e269. doi: 10.1016/S1470-2045(20)30723-3
Солопова Г.Г., Масчан А.А., Новичкова Г.Г. «Рекомендации 2020 года по диагностике и терапии инвазивного аспергиллеза у детей с онкогематологическими заболеваниями». Вопросы гематологии/онкологии и иммунопатологии. 2020 т.19 №1, стр. 158-166
Dolton MJ, Ray JE, Chen Sh.A., Ng K., Pont LG and McLachlan AJ. Multicenter study of voriconasol pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother, 2012; 59(9): 4793-4799
Dolton MJ, Ray JE, Chen Sh.A., Ng K., Pont LG and McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother, 2012; 56(11): 5503-5510
De Pauw B., Walsh T.J., Donnelly J.P., Stevens E.E., Edwards J.E. et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008; 46(12): 1813-1821
Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis, 2016; 63(4): e1 – e60
Cordonnier C., Rovira M., Maertens J., Olavarria E., Faucher C. et al. () Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: Results of the VOSIFI study. Haematologica, 2010; 95: 1762–1768
Dulley FL, Vigorito AC, Aranha FJ, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33(1):9-13. doi:10.1038/sj.bmt.1704325
Xu LP, Zhang XH, Wang FR, et al. Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2017;52(3):381-387. doi:10.1038/bmt.2016.28
Kharya G et al. Impact of Conditioning Regimen and Graft-versus-Host Disease Prophylaxis on The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation for High-Risk Severe Aplastic Anemia in Children and Young Adults: A Report from the Pediatric Severe Aplastic Anemia Consortium of India. Transplant Cell Ther. 2023 Mar;29(3):199.e1-199.e10.
Chen X, Wei J, Huang Y, et al. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2018;24(1):86-90.
Samarasinghe S, Veys P, Vora A, Wynn R. Paediatric amendment to adult BSH Guidelines for aplastic anaemia. Br J Haematol. 2018;180(2):201-205. doi:10.1111/bjh.15066
Ratanatharathorn V, et alet al. Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation. Blood, 1998 Vol. 7, № 1. P. 2303-14]
Storb R. et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. // Blood. United States, 1994. Vol. 83, № 9. P. 2749–2750.
Locatelli F. et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized // Blood. The American Society of Hematology, 2000. Vol. 96, № 5. P. 1690–1697.
Boelens JJ. et al. GVHD Prophilaxis // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Sureda A. et al. Springer, 2024. P. 219–228.
Holler E. et al. Acute Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Sureda A. et al. Springer, 2024. P. 385–394.
Nash R.A. et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
Klein OR, Buddenbaum J, Tucker N, et al. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017;23(2):325–32
Xu L.P. et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia // Bone Marrow Transplant. 2012. Vol. 47, № 12. P. 1507–1512.
Zhu H. et al. Unmanipulated haploidentical haematopoietic stem cell transplantation for children with severe aplastic anaemia // Br. J. Haematol. 2016. Vol. 174, № 5. P. 799–805.
Anderlini P. et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: A phase 1-2 dose de-escalation study // Lancet Haematol. Elsevier Ltd, 2015. Vol. 2, № 9. P. e367–e37
Трахтман П. Е. Аллогенная трансплантация гемопоэтических стволовых клеток в лечении врожденных и приобретенных незлокачественных заболеваний у детей (диссертация на соискание ученой степени доктора медицинских наук) – 2011.
Kahl C. et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: A long-term follow-up // Br. J. Haematol. 2005. Vol. 130, № 5. P. 747–751.
Erin Gatza et al. Prevention and treatment of acute grft-versus-host disease in children, adolescents and young adults. Biol Blood marrow Transplant 2020; May; 26(50: e101-e112.
Радыгина С.А., c соавт. Оценка эффективности использования абатацепта для профилактики острой реакции трансплантат против хозяина после трансплантации гемопоэтических стволовых клеток у детей с незлокачественными заболеваниями. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019, №2 (18), 22-29
Shelikhova L, Ilushina M, Shekhovtsova Z, et al. alphabeta T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation without Antithymocyte Globulin in Children with Chemorefractory Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2019;25(5):e179–e82
Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001 Dec 27;72(12):1924-9.
Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014;123(13):2017–25
Wei X, Xie Y, Jiang R, Li H, Wu H, Zhang Y, Li L, Zhou S, Ma X, Tang Z, He J, Wu D, Wu X. The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study. Front Immunol. 2022 Aug 31;13:967026.
Boelens JJ. et al. GVHD Prophilaxis // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Sureda A. et al. Springer, 2024. P. 219–228
Белобородов В.Б., Голощапов О.В., Гусаров В.Г., Дехнич А.В., Замятин М.Н., Зубарева Н.А., Зырянов С.К., Камышова Д.А., Климко Н.Н., Козлов Р.С., Кулабухов В.В., Петрушин М.А., Полушин Ю.С., Попов Д.А., Руднов В.А., Сидоренко С.В., Соколов Д.В., Шлык И.В., Эйдельштейн М.В., Яковлев С.В. Методические рекомендации Российской некоммерческой общественной организации «Ассоциация анестезиологов-реаниматологов», Межрегиональной общественной организации «Альянс клинических химиотерапевтов и микробиологов», Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии (МАКМАХ), общественной организации «Российский Сепсис Форум» «Диагностика и антимикробная терапия инфекций, вызванных полирезистентными штаммами микроорганизмов» (обновление 2022 г.). Вестник анестезиологии и реаниматологии. 2022;19(2):84-114. https://doi.org/10.21292/2078-5658-2022-19-2-84-114
Cattaneo C. et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria // Annals of Hematology, 2018 Vol.97, p. 1717-1726.
Miranda M., Nadel S. Pediatric Sepsis: a Summary of Current Definitions and Management Recommendations // Curr Pediatr Rep. Springer Nature, 2023. Vol. 11, № 2. P. 29–39.
Licciardello M. et al “Prophylaxis and therapy of viril infections in pediatric patients treated for malignancy” Pediatr Rep 2011; 3(1):13-16
Brennan M.T. et al “Oral manifestations in patients with aplastic anemia”. Oral Surg Oral Med Oral Pathol Oral Endod 2001; 92(5):503-8
Righini-Grunder F et al/ Frequency of oral mucositis and local virus reactivation in herpes simplex virus seropositive children with myelosupressive therapy// Klin Padiatr. 2015; 227(6-7): 335-8
Arghya S. et al “Clinical profile and microbiologic spectrum of febrile neutropenic episodes in children with severe aplastic anemia” J Pediatr Hematol Oncol. 2024; 42(3):193-197
Liu L-P et al High risk of bloodstream infection of carbapenem-resisstant Enterobacteriaceae carriers in neutropenic children with hematological diseases.//Antimicrob Resist Infect Control.2023; 12(1):66
Castagnola E. Et al/ Antibiotic Resistant Bloodstream Infections in Pediatric Patients Receveiving Chemotherapy or Hematopoietic Stem Cell Transplant: Factors Associated with Development of Resistance, Intensive Care Admission and Mortality// Antibiotics 2021; 10(3): 266
Kontou A. et al. Use of newer and repurposed antibiotics against gram-negative bacteria in neonates.// Antibiotics 2023; 12(6):1072
Chiotos K. et al Treatment of carbapenem-resistant Enterobacteriaceae infections in children
Hassan H et al Dosage regimen for meropenem in children with Pseudomonas infections do not meet serum concentration targets.//Clin Transl Sci 2020; 13(2):301-308
Chu-Han G. et al Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns.// Ther Clin Risk Manag. 2014; 27(10):217-227
Gonzalez D et al Use of opportunistic clinical data and a population pharmacokinetics model to support dosing of clindamycin for premature infants to adolescents.//Clin Pharmacol Ther 2014; 96(4): 429-437
Aslan K. et al Clinical and laboratory responses to tigecycline in children.// J Clin Pharm Ther 2022; 47(10):1585-1590
Venuti F. et al. Novel beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review. Microorganisms 2023;11(7):1798
Soler-Palacin P. et al Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective trile. J Antimicrob Chemother 2012; 67(3):700-706
5.Hsu AJ. Et al Challenges in the treatment of invasive aspergillosis in immunocompromised children.//Antimicrob Agents Chemother 2022; 66(7): e02156-21
Decembrino N et al A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation.// Antimicrob Agents Chemother 2020; 64(3): e01783-19
Fernandez Ladesma B et al Isavuconazole use and TDM in real-word pediatric practice.// Antimicrob Agents Chemother 2023; 67(12): e00829-23
Prout A.J. et al @Bacterial and fungal etiology of sepsis in children in United States: recjnsidering empiric therapy”.Critical Care Medicine 2020;48(3):192-199
Tan X. et al “Comparative efficacy and safety of antipseudomonal b-lactams for pediatric febrile neutropenia”. Medicine (Baltimore)2021;100(50):27266
Cепсис у детей с онкологическими заболеваниями : учебно-методическое пособие / Н. В. Матинян, Н. Ю. Епифанова, Т. В. Горбунова [и др.]. — Москва : ГЭОТАР-Медиа, 2023. — 48 с. — DOI: 10.33029/9704-7973-5-SCC-2023-1-48.
Cornely O.A. et al Global guidline for the Diagnosis and Treatment of Mucormycosis:an initiative of the Europian Confederation of Medical Mycology in cooperation with the Mycosis Study Group Education and Research Consortium. Lancet Infect Dis 2019;19(12):405-421
Di Pasquale M.F. et al “Prevalence and Etiology of community-acquired pneumonia in immunocompromised patients” Clin Infect Dis 2019 24;68(9):1482-1493